Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.23 USD
Change Today -0.007 / -3.00%
Volume 957.6K
HEB On Other Exchanges
As of 8:04 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One Penn Center

1617 JFK Boulevard

Suite 500

Philadelphia, PA 19103

United States

Phone: 215-988-0080

Fax: 215-988-1739

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system improving technologies for the treatment of viral and immune based chronic disorders. The company’s strategic focus is derived from four applications of its two core pharmaceutical technology platforms Ampligen and Alferon N Injection. The commercial focus for Ampligen includes application as a treatment for CFS and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is an FDA approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. The company’s primary pharmaceutical product platform consists of its experimental compound, Ampligen, its FDA approved natural interferon product, Alferon N Injection, and its experimental liquid natural interferon for oral administration, Alferon LDO (Low Dose Oral). Ampligen Ampligen is an experimental drug undergoing clinical development for the treatment of CFS. The company’s drug technology utilizes specifically-configured RNA. Its double-stranded RNA drug product, trademarked Ampligen, is an experimental, unapproved drug, that would be administered intravenously. Ampligen has been assigned the generic name rintatolimod by the United States Adopted Names Council (USANC) and has the chemical designation poly(I) poly(C12U). In 2012, the company filed a new drug application for Ampligen with the ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica), the agency responsible for the national regulation of drugs, foods and medical technology in Argentina, under the ANMAT’s Orphan Drug regulations. Alferon N Injection Alferon N Injection is the registered trademark for the company’s injectable formulation of natural alpha interferon, which is approved by the FDA for the treatment of certain categories of genital warts. Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional (within lesions) treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. Certain types of human papilloma viruses (HPV) cause genital warts, a sexually transmitted disease (STD). Alferon N Injection contains a multi-species form of alpha interferon. Alpha interferons are manufactured commercially in three ways: by genetic engineering, by cell culture, and from human white blood cells. Research and Development The company’s research and development projects are targeting treatment therapies for CFS, various cancers (as adjunctive therapy), and other viral diseases, such as prevention and treatment of seasonal and pandemic H1N1 or influenza. In 2012, the ANMAT approved the sale and distribution of Alferon N Injection (under the brand name Naturaferon) in Argentina. Alferon LDO (Low Dose Oral) Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)] is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon. Patents and Non-Patent Exclusivity Rights As of December 31, 2013, the company had 25 patents worldwide with 50 additional pending patent applications comprising its intellectual property. In 2013, the company granted four new patents, one in Singapore for the use of Ampligen to initiate innate immunity and to treat or prevent viral infections and tumors, and three for the use of Alferon LDO to treat bacterial or protozoan infections in Australia, New Zealand and Singapore. With respect to Ampligen, the main U.S. CFS treatment patent (#6,130,206) expires October 10, 2017. Significant Events In July 2014, Hemispherx Biopharma, Inc. announced a strategic alliance to develop multiple projects with Bioclones (Pty) Ltd. In October 2014, Hemispherx Biopharma, Inc. has announced new research collaborations designed to develop therapeutic cocktails against Ebola which may overcome the emergence of drug resistance due to Ebola virus mutation. History Hemispherx Biopharma, Inc. was founded in 1990.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.23 USD -0.007

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $306.81 USD -6.27
AstraZeneca PLC 4,373 GBp -119.50
Baxter International Inc $66.61 USD -0.54
Medigene AG €8.42 EUR -0.10
Sarepta Therapeutics Inc $25.62 USD +0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 317.0x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 236.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at